Search

Displaying results 2841 - 2850 of 10000 in total
  1. Drug

    Gancotamab

    go.drugbank.com/drugs/DB14784
    Investigational

    Gancotamab is under investigation in clinical trial NCT02213744 (MM-302 Plus Trastuzumab vs.

  2. Drug

    Belapectin

    go.drugbank.com/drugs/DB15125
    Investigational

    Belapectin is under investigation in clinical trial NCT02575404 (GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients).

  3. Drug

    Golodirsen

    go.drugbank.com/drugs/DB15593
    ApprovedInvestigational

    This is an X-linked condition leading to progressive muscle degeneration that begins in early childhood, rendering many patients wheelchair-bound by age 12. … [L10773] Golodirsen was developed by Sarepta Therapeutics and granted accelerated FDA approval on December 12, 2019 due to the urgent need for this drug in patients suffering from a certain form of

  4. Drug

    Fluindione

    go.drugbank.com/drugs/DB13136
    ApprovedWithdrawn

    Fluindione is under investigation for the treatment of Venous Thrombosis, Pulmonary Embolism, Permanent Atrial Fibrillation, and Anticoagulating Treatment on a Duration at Least 12-month-old Superior.

  5. Drug

    Shark liver oil

    go.drugbank.com/drugs/DB11088
    Approved

    However the major component is considered to be squalene, which may range up to 90% of the shark oil, depending on the species. … The potential benefit of shark oil has been experimented in different therapeutic implications, where it is claimed to improve immune responses and exert an antitumor activity.

    Mixtures: DG Health Hemorrhoidal
  6. Drug

    Zileuton

    go.drugbank.com/drugs/DB00744
    ApprovedWithdrawn

    Specifically, it inhibits leukotriene LTB4, LTC4, LTD4, and LTE4 formation. Both the R(+) and S(-) enantiomers are pharmacologically active as 5-lipoxygenase inhibitors in in vitro systems.

  7. Drug

    Odesivimab

    go.drugbank.com/drugs/DB15900
    ApprovedInvestigational

    Ebola virus (EBOV) remains an important human pathogen within the _Ebolavirus_ genus, having been responsible for at least 17 known outbreaks with an average case fatality rate of 43.92%.

  8. Drug

    Rezafungin

    go.drugbank.com/drugs/DB16310
    ApprovedInvestigational

    Rezafungin has a half-life higher than 130 hours and can be administered once a week instead of daily. … [L45633,L45658] It was subsequently approved in the EU in November of the same year. [L52745]

  9. Drug

    Antazoline

    go.drugbank.com/drugs/DB08799
    Approved

    It is used to relieve nasal congestion. It is also formulated as eye drops with naphazoline to relieve allergic conjunctivitis.

    Mixtures: SULFARHIN BURUN MERHEMI, 20 G, SULFARHIN BURUN MERHEMI, 12 G
  10. Drug

    Lunsotogene parvec

    go.drugbank.com/drugs/DB18278
    ApprovedInvestigational

    and approval of just 61 days. … [L56137] It acts by delivering functional copies of the human _OTOF_ gene specifically to inner hair cells via an engineered hair-cell-specific Myo15 promoter, which restores essential synaptic transmission